European Journal of Medicinal Chemistry p. 457 - 467 (2017)
Update date:2022-07-30
Topics:
Du, Yongli
Song, Lianhua
Zhang, Liudi
Ling, Hao
Zhang, Yanhui
Chen, Haifei
Qi, Huijie
Shi, Xiaojin
Li, Qunyi
The estrogen-related receptor α (ERRα) is an orphan receptor and a novel target for solid tumor therapy, conceivably through effects on the regulation of tumor cell energy metabolism associated with energy stress within solid tumor micro environments. Here we describe the discovery of novel potent inverse agonists of ERRα. In?vitro, compound 11 potently inhibits ERRα’s transcriptional activity by preventing endogenous PGC-1α and ERRα binding and suppresses the proliferation of different human cancer cell lines and the migration of breast cancer cells (MDA-MB-231). In?vivo, compound 11 demonstrates a strong inhibitory effect on the growth of human breast cancer xenografts (MDA-MB-231) and the tumor growth is inhibited by 40.9% after treating with compound 11 (30?mg/kg). The binding mode shows that compound 11 interacts with the binding pocket of ERRα through hydrogen interactions with the residue Gly397 and hydrophobic interactions with the hydrophobic residues. All these results suggest that compound 11 represents a novel potent ERRα inverse agonist and is promising in the discovery of antitumor compounds for the treatment of triple negative breast cancer.
View MoreJiangsu Jiuri Chemical Co.,Ltd.
Contact:+86-519-82118868
Address:Tianwang Town, Jurong City, Jiangsu Province, China
Shanghai Kefu Chemical Co.,Ltd.
Contact:+86-21-34616196
Address:Room601-602, Xuhui Business Building, No.168, Yude Road, Shanghai
Contact:+86-25-85281586
Address:13F,Bld2#,South of Longpan Road
LIAONING DMSO CHEMICALS CO.,LTD.
website:http://www.chinadmso.com
Contact:+86-427-6503033
Address:FLOOR 16, BLOCK A, FINANCIAL SQUARE, XINGLONGTAI DISTRICT, PANJIN CITY, LIAONING P.R. CHINA
Jinan Trio PharmaTech Co., Ltd
Contact:86-531-88811783;+(0)13153010282
Address:2766 Yingxiu Road, Jinan High-Tech Zone, China
Doi:10.1016/j.ejmech.2013.01.001
(2013)Doi:10.1016/j.bmc.2020.115967
(2021)Doi:10.1039/b702606d
(2007)Doi:10.1016/j.tetasy.2007.04.020
(2007)Doi:10.1002/cssc.201601878
(2017)Doi:10.1021/jo070732a
(2007)